2023-11-24 17:19:00
:
SSRI may provide relief for post-covid syndrome, study suggests
A recent study published in Nature Scientific Reports suggests that selective serotonin reuptake inhibitors (SSRIs) may be beneficial for individuals suffering from post-covid syndrome. The study, led by Carla Rus et al., followed 95 patients with post-covid syndrome for an average of fifteen months and found promising results.
The patients, who were diagnosed by their general practitioner or medical specialist, reported significant improvement in their symptoms after taking SSRIs such as fluvoxamine, citalopram, escitalopram, and fluoxetine. The researchers recommended increasing the dose of the SSRIs based on the patient’s response and side effects.
According to the study, the patients experienced a 63 percent reduction in post-covid symptoms after starting the SSRI treatment. Specifically, symptoms such as brain fog and overstimulation decreased significantly. However, it is important to note that the study does have limitations. The researchers did not conduct a placebo-controlled study, and the outcome measures were based solely on self-reported questionnaires, which may introduce bias.
While the findings are certainly promising, additional research is needed to confirm the efficacy of SSRIs in treating post-covid syndrome. Despite the limitations of the study, the results have sparked interest in further exploring the potential benefits of SSRIs for individuals struggling with long-term symptoms of covid-19.
It is important to consult with a healthcare professional before starting any new treatment regimen for post-covid syndrome. The researchers hope that their study will spark further investigation and ultimately lead to more effective treatments for individuals suffering from post-covid syndrome.]
#Exploratory #study #antidepressants #long #Covid #positive